Enterprise value to EBIT forward of SkinHealth Systems Inc. Class A – TRADEGATE:V7A
The article presents financial data for SkinHealth Systems Inc. Class A (TRADEGATE:V7A), specifically focusing on its enterprise value to EBIT forward. It notes that there are currently no trades for this stock on TRADEGATE. The content appears to be a financial data page from TradingView, providing an overview of the company's financials without detailed analysis.
Gross margin % of SkinHealth Systems Inc. Class A – FWB:V7A
This article displays the gross margin percentage for SkinHealth Systems Inc. Class A, traded on the FWB exchange under the symbol V7A. The content indicates "No trades" and presents a structure for financial data, though no specific values are provided. It appears to be a stub or template page from a financial data platform.
Weekly Recap: 2026 outlook revised and 1-for-20 reverse split
SkinHealth Systems Inc. (SKIN) has updated its 2026 financial outlook, narrowing revenue guidance to $281M–$287M while increasing adjusted EBITDA guidance to $48M–$50M, attributing a weak Q4 outlook to poor equipment sales, lower margins, and higher expenses. The company also executed a 1-for-20 reverse stock split on October 14, 2026, launched its HydraClear Treatment Booster, and expanded SkinStylus availability to six European markets during Q3 2026. Additionally, SkinHealth Systems introduced a U.S. provider rental program in Q3, though its impact on results is still being evaluated.
Total equity of SkinHealth Systems Inc. Class A – LS:A42J03
The article provides a financial snapshot of SkinHealth Systems Inc. Class A (LS:A42J03), focusing on its total equity. It notes that there have been no recent trades for this stock. The data presented is sourced from ICE Data Services and FactSet.
Sales fell 2.1%, but the Q3 loss narrowed at SkinHealth Systems (SKIN).
SkinHealth Systems (SKIN) reported Q3 2026 net sales of $69.2 million, a 2.1% decrease from the prior year, primarily due to lower Delivery Systems sales, though Consumables sales increased slightly. The company's net loss significantly narrowed to $0.9 million from $11.0 million, and adjusted EBITDA improved to $13.4 million from $8.9 million. SkinHealth Systems also provided updated fiscal 2026 guidance, projecting net sales between $281 million and $287 million and adjusted EBITDA of $48 million to $50 million, while announcing a 1-for-20 reverse stock split and the retirement of its 2026 Notes.
Zero voting power accompanies Abigail P. Johnson’s reported SkinHealth Systems (SKIN) stake.
FMR LLC and Abigail P. Johnson each reported beneficial ownership of 5,476,327 shares, or 4.2%, of SkinHealth Systems Inc. Class A common stock as of September 30, 2026. While FMR LLC holds sole voting power over most of its shares, Abigail P. Johnson reported no voting power for her identical stake, only sole dispositive power. The SEC filing (SCHEDULE 13G/A) indicates a neutral sentiment and impact on the stock.
Return on equity % of SkinHealth Systems Inc. Class A – SWB:V7A
This article presents the Return on Equity (ROE) percentage for SkinHealth Systems Inc. Class A, traded on the SWB exchange under the symbol V7A. It indicates that there are currently no trades for this stock. The page is part of TradingView's financial data section, providing an overview of the company's financials.
V7A Forecast — Price Target — Prediction for 2027
The article provides a forecast for SkinHealth Systems Inc. Class A (V7A), including a price target of 15.82 USD from 6 analysts, with estimates ranging from 10.00 USD to 30.00 USD. It also details recent EPS performance, revenue forecasts for the next quarter, and a current "Neutral" analyst rating based on 9 analysts' opinions. The content emphasizes how to interpret these financial metrics and what complementary analyses to consider.
Basic earnings per share (basic EPS) of SkinHealth Systems Inc. Class A – SWB:V7A
This article presents the basic earnings per share (basic EPS) for SkinHealth Systems Inc. Class A, traded on the SWB exchange under the ticker V7A. It appears to be a financial data snippet from TradingView, focusing solely on this specific financial metric. The content highlights the company's financials without providing detailed figures.
SkinHealth Systems Inc. Class A Estimates – MUN:V7A
This page provides financial estimates for SkinHealth Systems Inc. Class A (MUN:V7A) on the Munich Stock Exchange, covering income statements, balance sheets, cash flow, and valuation metrics. Users can explore reported financial data and analyst estimates, compare actual results with average, high, and low estimates, and visualize trends over time. The platform explicitly states that the information is not investment advice and encourages users to conduct their own research.
Return on assets % of SkinHealth Systems Inc. Class A – MUN:V7A
This article provides the "Return on assets %" for SkinHealth Systems Inc. Class A (MUN:V7A), listed on the Munich Stock Exchange. The page indicates that the market is currently closed with no trades. It also details the various data sources and copyright information for the financial and reference data presented.
SkinHealth Systems Inc. Class A Revenue Breakdown – MUN:V7A
SkinHealth Systems Inc. Class A (MUN:V7A) generated €256.11 million in revenue last year. The "Consumables" segment was the top performer, contributing €181.11 million, while the Americas region accounted for the largest geographical share with €173.67 million in revenue.
Total liabilities of SkinHealth Systems Inc. Class A – FWB:V7A
This article briefly presents the total liabilities of SkinHealth Systems Inc. Class A, traded on the Frankfurt Stock Exchange under the symbol V7A. It indicates that the market was closed with no trades recorded at the time of publication, and financial data is provided by ICE Data Services and FactSet.
Dilution adjustment of SkinHealth Systems Inc. Class A – GETTEX:V7A
This article announces a dilution adjustment for SkinHealth Systems Inc. Class A, trading under the symbol V7A on Gettex. The notice appears to be a standard financial update regarding the company's stock.
Net margin % of SkinHealth Systems Inc. Class A – LSX:A42J03
The article presents the net margin percentage for SkinHealth Systems Inc. Class A (LSX:A42J03), a company listed on the Lang & Schwarz Exchange under the Medical Specialties sector. It indicates that the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet.
Gross profit of SkinHealth Systems Inc. Class A – LSX:A42J03
This article provides financial information for SkinHealth Systems Inc. Class A (LSX:A42J03), specifically focusing on its gross profit. The data is available through TradingView, which sources market data from ICE Data Services and reference data from FactSet. The page indicates that the market is currently closed with no trades.
Total debt per share of SkinHealth Systems Inc. Class A – MUN:V7A
The article title states that it pertains to the "Total debt per share of SkinHealth Systems Inc. Class A – MUN:V7A". However, the body of the article is empty beyond the title and navigation links, indicating that the content regarding the debt per share was not provided. The page appears to be a financial data portal, likely from TradingView, for the Munich Stock Exchange.
Tangible book value per share of SkinHealth Systems Inc. Class A – FWB:V7A
The article displays the tangible book value per share for SkinHealth Systems Inc. Class A, traded on the Frankfurt Stock Exchange under the symbol V7A. It indicates that the market is currently closed with no trades. The information is presented by TradingView, with market data from ICE Data Services and reference data from FactSet.
Basic earnings per share (basic EPS) of SkinHealth Systems Inc. Class A – LSX:A42J03
This article displays the basic earnings per share (basic EPS) for SkinHealth Systems Inc. Class A (LSX:A42J03). It provides financial data, including period, value, change, and change percentage for the company's basic EPS. The content is sourced from FactSet and ICE Data Services, among others.
Return on invested capital % of SkinHealth Systems Inc. Class A – FWB:V7A
This article focuses on the "Return on invested capital %" for SkinHealth Systems Inc. Class A, traded on the Frankfurt Stock Exchange under the symbol FWB:V7A. It appears to be a financial data page from TradingView, providing an overview of the company's financial performance metric. The page indicates that the market was closed at the time of access.
Free cash flow of SkinHealth Systems Inc. Class A – FWB:V7A
The article focuses on the free cash flow information for SkinHealth Systems Inc. Class A, trading under the ticker V7A on the Frankfurt Stock Exchange. It provides financial data within the TradingView platform, noting that the market was closed at the time of publication and no trades were recorded.
SkinHealth Systems Inc. Class A Earnings and Revenue – GETTEX:V7A
SkinHealth Systems Inc. (GETTEX:V7A) recently reported earnings per share of -0.35 EUR, surpassing analyst estimates by 20%, though revenue of 63.13M EUR missed the 65.19M EUR estimate. Analysts anticipate -1.12 EUR EPS and 59.84M EUR revenue for the upcoming quarter. The report provides a snapshot of past performance and future expectations for the company.
SkinHealth Systems Inc. Class A Earnings and Revenue – FWB:V7A
SkinHealth Systems Inc. (FWB:V7A) recently reported earnings per share of -0.35 EUR, surpassing analyst estimates by 20.00%. However, revenue for the same period, at 63.13M EUR, fell short of the 65.19M EUR estimate. Analysts anticipate -1.12 EUR in EPS and 59.84M EUR in revenue for the upcoming quarter.
SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock?
SkinHealth Systems Inc. (SKIN) shares jumped 9% after completing a 1-for-20 reverse stock split, which helped the company regain compliance with Nasdaq's minimum bid price requirement. Despite this surge, analysts note that the consensus EPS estimate for the upcoming quarter has remained unchanged, suggesting that sustained upward momentum might require positive revisions in earnings estimates. The stock currently holds a Zacks Rank #3 (Hold).
Total common shares outstanding of SkinHealth Systems Inc. Class A – TRADEGATE:V7A
This article provides financial information for SkinHealth Systems Inc. Class A (TRADEGATE:V7A), specifically focusing on its total common shares outstanding. It highlights the availability of this data through TradingView, noting that the market is currently closed with no trades.
Price to earnings ratio of SkinHealth Systems Inc. Class A – TRADEGATE:V7A
This page from TradingView provides financial information specifically on the Price to Earnings ratio for SkinHealth Systems Inc. Class A, traded on the Tradegate Exchange under the symbol V7A. The content indicates that the market was closed at the time of viewing and no trades were recorded. It is a data page rather than an article with narrative content.
Tangible book value per share of SkinHealth Systems Inc. Class A – MUN:V7A
This article provides the tangible book value per share for SkinHealth Systems Inc. Class A, trading on the Munich Stock Exchange under the ticker V7A. It presents a simple financial data point, indicating the value and any change over a specified period. The information is made available by financial data providers like ICE Data Services and FactSet.
SkinHealth Systems approves 1-for-20 reverse stock split By Investing.com
SkinHealth Systems (NASDAQ:SKIN) announced that its Board of Directors approved a 1-for-20 reverse stock split of its Class A common stock, effective Tuesday at 12:00 a.m. ET. This action is intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The split will reduce outstanding shares from approximately 130.3 million to 6.5 million.
SkinHealth Systems Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance
SkinHealth Systems (SKIN) has announced a 1-for-20 reverse stock split of its Class A common stock, effective October 14, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. This action will reduce outstanding shares from approximately 130.3 million to 6.5 million and aims to increase the per-share trading price, though it carries potential risks like decreased liquidity. Stockholders will receive cash for any fractional shares, and their percentage ownership will remain largely unchanged.
SkinHealth Systems to Implement 1-for-20 Reverse Stock Split
SkinHealth Systems (SKIN) announced that its board of directors has approved a 1-for-20 reverse stock split. The article indicates that further details are available for subscribers, implying that the reverse split aims to adjust the company's stock structure.
SkinHealth Systems approves 1-for-20 reverse stock split
SkinHealth Systems (NASDAQ:SKIN) announced that its Board of Directors approved a 1-for-20 reverse stock split of its Class A common stock, effective Tuesday at 12:00 a.m. ET. This move is intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The reverse split will reduce outstanding shares from approximately 130.3 million to about 6.5 million.
The Beauty Health Company (NASDAQ:SKIN) Receives Average Rating of "Hold" from Brokerages
The Beauty Health Company (NASDAQ:SKIN) has an average "Hold" rating from seven analysts, with an average 12-month price target of $1.38. The company's shares opened at $0.63, near its 12-month low, and its recent earnings matched EPS expectations but missed revenue forecasts. Institutional investors own a significant portion of the company's stock.
SkinHealth Systems shareholders approve reverse stock split and adjournment measures
SkinHealth Systems Inc. (NASDAQ:SKIN) announced that shareholders approved a reverse stock split and a proposal for meeting adjournment at a recent special meeting. The reverse stock split will be between 1-for-5 and 1-for-20, determined by the board. This follows a mixed Q2 2026 earnings report, where revenue fell short of expectations but adjusted EBITDA surpassed guidance, leading to an increased full-year adjusted EBITDA outlook.
Over 114 million votes backed a reverse stock split at SkinHealth Systems (SKIN), with the ratio left to the board.
SkinHealth Systems Inc. stockholders have approved a reverse stock split for Class A common stock, allowing a ratio between 1-for-5 and 1-for-20, with the exact ratio to be determined by the board. The proposal received overwhelming support with over 114 million votes in favor, representing approximately 89.05% of eligible shares. Stockholders also approved the adjournment of the special meeting if further proxy solicitation or votes were needed.
Form 8K Skinhealth Systems Inc For: 28 September By Investing.com
This article reports on the filing of a Form 8K by Skinhealth Systems Inc. for September 28. It provides financial market data, including major indices and commodity prices, alongside various company stocks and market trends. The content also features articles on economic news and stock analysis.
SkinHealth Systems Expands SkinStylus® SteriLock® MicroSystem to Europe
SkinHealth Systems has expanded the availability of its SkinStylus® SteriLock® MicroSystem, a professional microneedling and nano-needling device, to key European markets including the UK, Ireland, Germany, France, Spain, and Portugal. This strategic move leverages Hydrafacial's existing commercial network to broaden SkinHealth Systems' medical aesthetics portfolio. The expansion aims to offer aesthetic professionals complementary solutions for a wider range of cosmetic skin concerns, supporting the company's growth into a comprehensive medical aesthetics ecosystem.
SkinHealth Systems (SKIN) expands CFO role to operations
SkinHealth Systems Inc. (SKIN) has promoted its CFO, Michael Monahan, to Chief Financial and Operating Officer, effective September 3, 2026. In this expanded role, Monahan will oversee financial operations, supply chain, manufacturing, logistics, and customer experience. His annual base salary will increase from $515,000 to $555,000, effective September 15, 2026.
SkinHealth Systems Launches Hydrafacial Impact to Help Providers Accelerate Practice Growth
SkinHealth Systems has launched Hydrafacial Impact, a national education program aimed at helping aesthetic practices maximize their Hydrafacial investment and achieve sustainable growth. The program will visit nine U.S. markets, offering expert instruction, peer collaboration, and case-based learning focused on operational drivers of practice performance. This initiative expands Hydrafacial's comprehensive provider training platform, which has already educated over 60,000 providers worldwide.
The Beauty Health Company (NASDAQ:SKIN) Receives Consensus Rating of "Hold" from Analysts
The Beauty Health Company (NASDAQ:SKIN) has received a consensus "Hold" rating from seven analysts, with an average 12-month price target of $1.375. Despite recent reductions in outlook from some firms, Roth Capital reaffirmed a "buy" rating. The company's stock opened at $0.69, near its 52-week low, and reported quarterly revenue below expectations with a loss of $0.02 per share.
SkinHealth Systems (SKIN) says COO Sheri Lewis will depart on August 28, 2026
SkinHealth Systems Inc. (SKIN) announced that Sheri Lewis will resign from her role as Chief Operations, Quality and Technology Officer, effective August 28, 2026, to pursue other business opportunities. Ms. Lewis notified the company on August 10, 2026, and her departure is not due to any disagreements with the company's management or board. This information was disclosed in an 8-K filing.
SkinStylus Receives New FDA Clearance
SkinHealth Systems Inc. announced that its SkinStylus microneedling device has received new FDA clearance for improving the appearance of periorbital wrinkles in adults aged 22 and older across all Fitzpatrick skin types. This expands the device's indications, reinforcing SkinHealth System’s commitment to science-backed innovation in medical aesthetics. The SkinStylus SteriLock MicroSystem, a Class II Medical Device, is also cleared for facial acne scars and surgical/traumatic hypertrophic scars on the abdomen.
SkinStylus Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
SkinHealth Systems Inc. announced that its SkinStylus microneedling device has received new FDA clearance for improving the appearance of periorbital wrinkles in adults aged 22 and older across all Fitzpatrick skin types. This makes SkinStylus the only microneedling device with FDA-cleared indications for facial acne scars, periorbital wrinkles, and abdominal scars. The clearance highlights the device's versatility and SkinHealth Systems' commitment to evidence-based innovation in medical aesthetics, with microneedling demand continuing to grow significantly.
SkinStylus Receives US FDA Clearance for the Improvement of Periorbital Wrinkles in All Skin Types
The US FDA has cleared SkinHealth Systems Inc's SkinStylus microneedling device for improving periorbital wrinkles in adults aged 22 and older across all Fitzpatrick skin types. This Class II Medical Device also has indications for facial acne scars and surgical/traumatic hypertrophic scars. Clinical studies demonstrated statistically and clinically meaningful improvements, with patients reporting a more comfortable procedure compared to other systems.
SkinStylus gets FDA clearance for eye wrinkles across all skin types
SkinHealth Systems (NASDAQ: SKIN) announced that its SkinStylus SteriLock MicroSystem received FDA clearance for improving periorbital wrinkles in adults 22+ across all Fitzpatrick skin types. This makes SkinStylus the only microneedling device with FDA-cleared indications for facial acne scars, periorbital wrinkles, and abdominal hypertrophic scars, positioning it strongly in the growing U.S. microneedling market. The company highlights the device's versatility and its complementary role with Hydrafacial treatments, with consumer spending on microneedling reaching approximately $330 million in 2025.
SKIN Stock Pops On Volume As Balance Sheet Draws Focus
SkinHealth Systems Inc. (SKIN) saw its stock surge by 36.3% on heavy trading volume, moving from sub-$0.80 to above $1.00 following reports of dermatology breakthroughs. Despite quarterly losses and significant long-term debt, the company's strong gross margins and positive EBITDA are drawing attention from traders. The price action indicates a short-term uptrend, with clear momentum and volatility that aligns with small-cap trading strategies.
SkinStylus® Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
SkinHealth Systems Inc. announced that its SkinStylus microneedling device has received new FDA clearance for improving periorbital wrinkles across all Fitzpatrick skin types. This expands the device's indications, which already include facial acne scars and abdominal scars. The company highlights the growing demand for microneedling, especially when paired with Hydrafacial treatments, emphasizing its commitment to science-backed innovation in medical aesthetics.
SkinHealth (NASDAQ: SKIN) outlines $18M securities class settlement
SkinHealth Systems Inc. (NASDAQ: SKIN) has agreed to a proposed settlement of $18 million for a federal securities class action lawsuit, pending court approval. The company will contribute $3 million from its own cash, with insurers covering the remaining $15 million. This settlement aims to resolve claims from investors who traded the company’s Class A common stock and related options between May 10, 2022, and November 13, 2023.
SkinHealth Systems to pay $3M as part of $18M proposed securities settlement
SkinHealth Systems has agreed to an $18 million securities-class-action settlement, with the company contributing $3 million and insurers covering the remaining $15 million. This settlement, which requires court approval, resolves the Alghazwi v. The Beauty Health Company case and does not constitute an admission of wrongdoing. Plaintiffs' attorneys' fees are estimated to be up to 30% of the total settlement.
SkinHealth Systems Inc. Class A (SKIN) Live Share Price, Invest From India
This article provides a detailed financial overview of SkinHealth Systems Inc. Class A (SKIN), including its live share price, performance metrics, and key fundamental indicators as of June 2026. It also includes analyst recommendations, target prices, and historical returns for Indian investors, along with quarterly and annual profit, loss, and cash flow statements, and key management details. The company, formerly known as The Beauty Health Company, is a global medical aesthetics company known for its HydraFacial product and other skin health solutions.
Beauty Health Settles Investors’ Spa Device Suit for $18 Million
Beauty Health Co. has agreed to pay $18 million to settle a proposed class action lawsuit. Investors claimed the company misrepresented the success of its Syndeo facial machine for spas. The settlement amount represents about 14% of the estimated maximum damages of $125 million, which investors say is well above the median for comparable cases.